Nick Leschly and Giovanni Caforio (Via Jeff Rumans and AP Images)
FDA slams bluebird and Bristol Myers with a surprise RTF on ide-cel, but execs insist they can overcome setback quickly
Bristol Myers and their partners at bluebird have been slammed with a refuse-to-file letter from the FDA for their closely watched myeloma drug ide-cel …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
